RAACENO: Reducing Asthma Attacks in Children using Exhaled Nitric Oxide as a biomarker to inform treatment strategy - a randomised controlled trial
Primary research question: Is a schedule of FeNO plus symptom treatment more efficacious in reducing asthma when compared to a symptom-only schedule? Secondary research questions: (1) Is a FeNO plus symptom treatment schedule more efficacious in improving asthma control and spirometry when compared to a symptom-only schedule? (2) Are there correlations between changes in repeated measurements of FeNO and sputum eosinophil count? (3) Is sputum eosinophilia associated with increased risk of asthma exacerbations but not asthma control over the following three months? (4) Is asthma treatment guided by symptoms plus FeNO more efficacious in reducing risk of asthma exacerbations where FeNO and sputum eosinophilia are concordant? (5) What are the relative costs, effects and cost-effectiveness of a FeNO plus symptom treatment schedule compared to a symptom-only schedule over 12 months? (6) Is FeNO plus symptom treatment acceptable to children and their parents? What are their and the research nurses’ perceptions?
More information on the project is available on the RAACENO website.
External collaborators: S Turner, H Morgan (HSRU, University of Aberdeen); S Fielding, D Price (Applied Health Sciences, University of Aberdeen); M Thomas (University of Southampton) and E Gaillard (University of Leicester)
Turner, S., Cotton, S.C., Emele, C.D., Thomas, R., Fielding, S., Gaillard, E.A., de Jongste, J.C., Morgan, H., Neilson, A.R., Norrie, J., Pijnenburg, M., Price, D. and Thomas, M. (2019) 'Reducing Asthma Attacks in Children using Exhaled Nitric Oxide as a biomarker to inform treatment strategy: a randomised trial (RAACENO)', Trials, 20(1), 573.